SYMTOMAX GROW HOUSES PREPARE FOR INFARMED INSPECTION

Symtomax have recently concluded the design and integration of their propagation houses with leading company AgroPharm that specialises in advanced solutions for the pharmaceutical medical cannabis industry. The designs which were submitted back in 2019 are based on the number of plants per cycle (45.000) 
The greenhouses will be utilised for the germination in our first stages of growing but can also be used in the vegetative stages for flowering. Olaf Van Tulder Technical Director said “we are delighted with the team and their efforts in ensuring that Symtomax are well equipped for the early stages of propagation this year” Works for the completion of these greenhouses is expected to be completed by the end of March, with Symtomax having completed land clearing works on 49 hectares of the land for both the propagation and greenhouse installations.

Infarmed have also notified Symtomax of their first stage inspection for this coming April, Paul Segal Symtomax chairman said on site “This project which begun over three years ago, with our license submission, plan designs and technical and ground reports,  and seeing now the progress with the installation of our grow houses and our scheduled first cultivation inspection is very rewarding and we are looking forward to our first harvest in September ” Symtomax have signed major offtake agreements with some of their European partners and look to fulfil their first orders by the end of the year.
The Symtomax cultivation site is  in the heart of the Alentejo region of Portugal.  Symtomax Lda are one of only a handful of companies that have been approved by Infarmed for the development  and implementation of the largest medical cannabis facility in Europe. Portugal enjoys some of the lowest production costs in Europe thanks in part to its temperate climate and Californian type weather conditions which are ideal for outdoor cannabis cultivation. Portugal’s cannabis industry is governed by Infarmed, a National Authority of Medicines and Health Products that requires companies to adhere to strict production standards.

SEE MORE